The cardiovascular effects of the antihypertensive drug debrisoquin: a contribution to the pharmacology of chronic treatment. I. One-week administration to dogs
- PMID: 660542
The cardiovascular effects of the antihypertensive drug debrisoquin: a contribution to the pharmacology of chronic treatment. I. One-week administration to dogs
Abstract
Debrisoquin (5 mg/kg/day) was administered to mongrel dogs on 7 consecutive days either i.v. or p.o. Sixteen hours after the last dose, the animals were anesthetized with chloralose-urethane and subjected to several hemodynamic and biochemical measurements which serve for a comparison with the results of the chronic treatment in a subsequent paper. Aortic blood pressure, cardiac output, heart rate (after vagotomy) and pressor responses to bilateral carotid occlusion were decreased by debrisoquin; cardiac contractility and left ventricular end-diastolic pressure remained unaffected. The fall in vascular resistance of the perfused hind legs which occurred after cutting the lumbar sympathetic chain was smaller after debrisoquin than in controls. Increases in perfusion pressure elicited in the hind legs by electrical stimulation of the peripheral end of the sectioned lumbar sympathetic chain or by i.a. injection of tyramine were inhibited by treatment with debrisoquin. The vascular responses to i.a. injections of norepinephrine, angiotensin and acetylcholine remained unchanged. Isolated perfused mesenteric artery preparations obtained from dogs pretreated with debrisoquin showed reduced pressor responses to periarterial nerve stimulation. Dose-response curves for the pressor effect of norepinephrine were not altered by debrisoquin. Debrisoquin administered i.v. or p.o. depleted to a similar extent the stores of norepinephrine in the heart, spleen, mesenteric and femoral arteries.
Similar articles
-
The cardiovascular effects of the antihypertensive drug debrisoquin: A contribution to the pharmacology of chronic treatment. II. Eight-week administration to dogs.J Pharmacol Exp Ther. 1978 Sep;206(3):535-44. J Pharmacol Exp Ther. 1978. PMID: 702320
-
Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs.J Pharmacol Exp Ther. 1985 Dec;235(3):798-809. J Pharmacol Exp Ther. 1985. PMID: 2934543
-
Effects of prostaglandin synthesis inhibition on sympathetic-and parasympathetic-mediated coronary hemodynamic responses.J Pharmacol Exp Ther. 1986 May;237(2):589-99. J Pharmacol Exp Ther. 1986. PMID: 3084760
-
Cardiovascular pharmacology of ASL-7022. III. Peripheral vascular adrenergic mechanisms.J Pharmacol Exp Ther. 1985 Mar;232(3):629-35. J Pharmacol Exp Ther. 1985. PMID: 2857783
-
Autonomic and cardiovascular effects of chronic delta9-tetrahydrocannabinol administration in mongrel dogs.Res Commun Chem Pathol Pharmacol. 1977 Apr;16(4):593-607. Res Commun Chem Pathol Pharmacol. 1977. PMID: 193167
Cited by
-
Association between sympathetic activity and the atherogenic serum cholesterol fraction.Klin Wochenschr. 1990 Mar 5;68(5):269-76. doi: 10.1007/BF02116055. Klin Wochenschr. 1990. PMID: 2182939 Clinical Trial.